Linda Mileshkin

A nurse- and peer-led psycho-educational intervention to support women with gynaecological cancers receiving curative radiotherapy: The PeNTAGOn randomised controlled trial - ANZGOG 1102.

P Schofield, K Gough, M Pascoe, R Bergin, K White, L Mileshkin, D Bernshaw, N Kinnane, M Jackson, V Do, A Brand, S Aranda, R Cheuk, A Drosdowsky, S Penberthy, I Juraskova

Journal article  |  2020  |  Gynecologic Oncology

OBJECTIVE: Radiotherapy for gynaecological cancer is associated with multiple adverse effects. This randomised controlled trial ev..

A systematic review of the impact of contemporary treatment modalities for cervical cancer on women's self-reported health-related quality of life.

LM Wiltink, M King, F Müller, MS Sousa, M Tang, A Pendlebury, J Pittman, N Roberts, L Mileshkin, R Mercieca-Bebber, M-A Tait, R Campbell, C Rutherford

Journal article  |  2020  |  Supportive Care in Cancer

PURPOSE: Given the high survival rate of cervical cancer patients, understanding women's health-related quality of life (HRQL) dur..

Sex differences in oncogenic mutational processes.

Constance H Li, Stephenie D Prokopec, Ren X Sun, Fouad Yousif, Nathaniel Schmitz, undefined PCAWG Tumour Subtypes and Clinical Translation, Paul C Boutros, undefined PCAWG Consortium

Journal article  |  2020  |  Nature Communications

Sex differences have been observed in multiple facets of cancer epidemiology, treatment and biology, and in most cancers outside t..

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Journal article  |  2020  |  CLINICAL CANCER RESEARCH

Abstract High-grade serous ovarian cancer (HGSOC) accounts for the majority of ovarian cancer and has a dismal prognosis. PARP inh..

Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study

T Sivakumaran, L Mileshkin, P Grant, L Na, A DeFazio, M Friedlander, A Obermair, PM Webb, G Au-Yeung

Journal article  |  2020  |  Gynecologic Oncology

OBJECTIVES: To determine the impact of chemotherapy dose reductions and dose delays on progression-free survival (PFS) in women wi..

Inhibition of RNA polymerase I transcription activates targeted DNA damage response and enhances the efficacy of PARP inhibitors in high-grade serous ovarian cancer.

Elaine Sanij, Katherine Hannan, Jiachen Xuan, Shunfei Yan, Jessica A Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Sarah Ellis, Carleen Cullinane, Gretchen Poortinga, Kum Kum Khanna, Linda Mileshkin, Grant A McArthur, John Soong, Els M Berns, et al.

Conference Proceedings  |  2020  |  Clinical Cancer Research

CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer

Elaine Sanij, Katherine M Hannan, Jiachen Xuan, Shunfei Yan, Jessica E Ahern, Anna S Trigos, Natalie Brajanovski, Jinbae Son, Keefe T Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J Deans, Kum Kum Khanna, et al.

Journal article  |  2020  |  NATURE COMMUNICATIONS

Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cance..

Importance of Histological Subtyping in TP53 Mutant Endometrial Carcinomas

Alicia Leon-Castillo, Stephanie de Boer, Naveena Singh, Linda Mileshkin, Anthony Fyles, Alexandra Leary, Christine Haie-Meder, Vincent Smit, Godfrey Wilson, Remi Nout, Nanda Horeweg, Carien Creutzberg, Tjalling Bosse

Conference Proceedings  |  2020  |  LABORATORY INVESTIGATION

Importance of Histological Subtyping in TP53 Mutant Endometrial Carcinomas

Alicia Leon-Castillo, Stephanie de Boer, Naveena Singh, Linda Mileshkin, Anthony Fyles, Alexandra Leary, Christine Haie-Meder, Vincent Smit, Godfrey Wilson, Remi Nout, Nanda Horeweg, Carien Creutzberg, Tjalling Bosse

Conference Proceedings  |  2020  |  MODERN PATHOLOGY

Understanding and information needs of cancer patients regarding treatment-focused genomic testing: A systematic review

Kamil Wolyniec, Jessica Sharp, Smaro Lazarakis, Linda Mileshkin, Penelope Schofield

Journal article  |  2020  |  Psycho-Oncology

OBJECTIVE: To systematically review literature exploring experiences of cancer patients regarding their understanding of treatment..